In the second-line treatment, tremelimumab (a monoclonal antibody targeting CTLA4) administered at a dose of 15 mg/kg i.v. every 90 days was first evaluated in a single-arm phase II multicenter clinical trial with a sample of twenty patients with advanced HCC and hepatitis C infection etiology [30]. Here, CTLA4 is linked to hepatocellular carcinoma.